| Nov 14 |
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
|
| Nov 13 |
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
AcelRx Pharmaceuticals GAAP EPS of -$0.13 beats by $0.07
|
| Nov 13 |
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
AcelRx Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 6 |
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
|
| Oct 8 |
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
|
| Sep 5 |
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 19 |
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
|
